STOCK TITAN

Zomedica Corp - ZOM STOCK NEWS

Welcome to our dedicated page for Zomedica news (Ticker: ZOM), a resource for investors and traders seeking the latest updates and insights on Zomedica stock.

Overview

Zomedica Corp (NYSE American: ZOM) is an innovative veterinary healthcare company dedicated to enhancing animal health through advanced diagnostic and therapeutic solutions. Specializing in point-of-care technologies for companion animals and equines, the company offers a robust portfolio designed to address the unmet needs of clinical veterinarians and improve practice efficiencies. With a focus on novel diagnostic platforms and non-invasive therapeutic devices, Zomedica empowers veterinary professionals to lower operating costs, increase productivity, and ultimately deliver superior patient care.

Product Portfolio and Technological Innovations

Zomedica's offerings include an array of cutting-edge products that integrate advanced imaging, automated diagnostic capabilities, and innovative therapeutic modalities. The company is renowned for its TRUFORMA diagnostic platform, a system that utilizes proprietary sensor technologies for accurate and rapid testing. Alongside this, its digital cytology system and remote monitoring solutions enhance the precision of diagnoses and clinical decision-making. Additionally, Zomedica’s novel therapeutic devices are designed to accelerate healing processes and minimize patient discomfort through non-invasive methods.

Market Position and Competitive Edge

Operating within the broader veterinary health industry, Zomedica has established a strong market position by addressing both clinical and business challenges faced by veterinarians. The company differentiates itself with a deep commitment to research and development, leveraging the insights of practicing veterinary professionals to tailor its product suite. This focus on innovation has allowed Zomedica to not only meet the growing demand for efficient, point-of-care diagnostic tools but also to set new operational standards across veterinary practices. Its comprehensive solutions enable veterinarians to conduct tests quickly and accurately, thereby reducing turnaround times and enhancing patient care.

Operational Excellence and Global Reach

Headquartered in Michigan, Zomedica operates from world-class manufacturing and distribution facilities that underscore its commitment to quality and efficiency. With manufacturing operations in key U.S. regions, the company ensures consistent delivery of high-quality products to its domestic and international markets. Zomedica's strategic partnerships in various regions further complement its mission of expanding access to advanced veterinary care globally. The company’s investments in cleanroom technologies and automated production lines not only enhance manufacturing capacity but also streamline logistics and distribution processes.

Benefits to Veterinary Practices

The integrated solutions offered by Zomedica are specifically designed to improve the workflow and profitability of veterinary practices. By automating complex diagnostic procedures and providing rapid, lab-quality results at the point of care, the company enables veterinarians to focus on delivering improved patient outcomes. Enhanced diagnostic speed, reduced operational costs, and increased efficiency are key factors driving the widespread adoption of Zomedica’s technologies in veterinary clinics across varied market segments.

Commitment to Innovation and Quality Care

Underpinned by the insights of industry experts and built on robust scientific research, Zomedica remains committed to continuous improvement in veterinary care. The company’s strategic focus on innovation, combined with its rigorous quality control measures, supports a wide spectrum of diagnostic and therapeutic applications. This dedication not only bolsters the confidence of veterinary professionals in adopting its technologies but also reinforces the company’s reputation for excellence, expertise, and trustworthiness in the veterinary healthcare industry.

Conclusion

Zomedica Corp stands out as a pioneering force in the veterinary health sector by delivering comprehensive, technology-driven solutions that enhance both clinical outcomes and practice management. Through its innovative product portfolio and strategic operational excellence, Zomedica continues to influence the evolution of veterinary diagnostics and therapeutics, enabling veterinarians to provide top-tier care to companion and equine patients.

Rhea-AI Summary

Zomedica (NYSE American:ZOM), a veterinary health company specializing in point-of-care diagnostics and therapeutic products for equine and companion animals, has announced its participation in the upcoming Sidoti Micro Cap Conference on November 13-14, 2024. Larry Heaton, CEO, will deliver a presentation on November 14 at 11:30 ET and conduct one-on-one meetings with investors. The presentation will be accessible via webcast, with free registration available through Sidoti's website. A replay will be available on Zomedica's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
conferences
-
Rhea-AI Summary

Zomedica (NYSE:ZOM) reported Q3 2024 financial results with revenue growing 10% to $7.0 million, maintaining a strong gross margin of 72.3%. The Diagnostics segment grew 38%, while the Therapeutic Device segment increased 9%. Consumable revenues rose 6% to $4.8 million, and capital revenues increased 21% to $2.2 million. The company ended the quarter with $77.8 million in cash and equivalents. Operating expenses increased 21% to $12.5 million, resulting in a net loss of $6.7 million. The company received CE Mark approval for TRUVIEW and expanded international distribution agreements across Europe, Middle East, and Latin America.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
-
Rhea-AI Summary

Zomedica (NYSE American:ZOM) has launched the Ear Cytology Quick Scan protocol for its TRUVIEW digital microscope and telepathology platform. This new feature, available with the TRUprep automated slide preparation system, reduces ear cytology diagnostic time to just over four minutes, significantly improving veterinary practice workflow. The innovation addresses a growing market, with the Companion Animal Ear Infection Treatment Market projected to reach $1.2 billion by 2032 from $648 million in 2023. The protocol targets otitis, which affects 15-20% of dogs and 4-7% of cats, enabling faster diagnosis of yeast, bacteria, and inflammation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
none
Rhea-AI Summary

Zomedica (NYSE American:ZOM), a veterinary health company specializing in point-of-care diagnostic and therapeutic products for equine and companion animals, has scheduled its Q3 2024 earnings conference call for November 7, 2024, at 4:30 p.m. ET. The call will cover operational and financial highlights for the quarter ended September 30, 2024, followed by a Q&A session. Participants can join via phone (+1-800-717-1738 U.S. Toll-Free or +1-646-307-1865 International) or webcast. A replay will be available until November 21, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
conferences earnings
-
Rhea-AI Summary

Zomedica Corp. (NYSE American:ZOM) has announced its sponsorship of educational programs at the upcoming Fetch Coastal conference in Atlantic City, NJ from October 14-16, 2024. The company will showcase its innovative veterinary products, including the TRUFORMA® diagnostic platform, TRUVIEW™ digital microscope, PulseVet® shock wave platform, and VETGuardian® remote monitor.

Zomedica is sponsoring presentations by leading veterinary experts, including:

  • Dr. Shadi J. Ireifej on Brachycephalic Airway Syndrome
  • Dr. Adam Christman on pain management modalities
  • Steve Dale on separation distress in pets
The company will be exhibiting at Booth #217 during the conference, which is described as a cornerstone event in the veterinary industry for the east coast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
none
-
Rhea-AI Summary

Zomedica Corp. (NYSE American:ZOM) has expanded its distribution partnership with Grovet in Europe for its equine PulseVet® and TRUFORMA product platforms. The updated agreement grants Grovet exclusive distribution rights in 27 European countries and non-exclusive rights in Italy and the UK. This expansion includes the introduction of the TRUFORMA equine platform to the European market, alongside existing equine assays for eACTH and Cortisol, with equine Insulin launching later this year.

Kevin Klass, Zomedica's Senior VP of Sales, expressed satisfaction with the expanded partnership, highlighting Grovet's success in distributing PulseVet products. Koen Schmitz, Managing Director of Grovet, emphasized the scientific basis of Zomedica's products. The TRUFORMA platform offers equine veterinarians the ability to diagnose and monitor conditions like PPID (Cushing's disease) with reference lab accuracy and point-of-care convenience.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none
Rhea-AI Summary

Zomedica Corp. (NYSE American:ZOM) has completed renovations at its 30,000-square-foot facility in Plymouth, Minnesota. The upgrades include an expanded cleanroom for manufacturing operations, installation of a new automated line for TRUFORMA® cartridge production, and improved distribution facilities for more efficient shipping. The new automated cartridge line can produce up to one million cartridges annually, significantly increasing manufacturing capacity to meet growing demand.

The TRUFORMA diagnostic platform uses Qorvo Inc.'s Bulk Acoustic Wave (BAW) sensor technology, offering veterinarians precise diagnostic measurements for thyroid and adrenal conditions, canine non-infectious gastrointestinal disease, and equine Cushing's disease. This renovation strengthens Zomedica's ability to meet customer demand while developing its expanding assay portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
none
-
Rhea-AI Summary

Zomedica Corp. (NYSE American:ZOM) has secured CE Mark approval for its TRUVIEW™ digital microscopy and telepathology platform, enabling commercialization across the European Economic Area. The TRUVIEW system integrates advanced diagnostic features, including LiquiView™ liquid lens technology and TRUprep™ automated slide preparation, enhancing diagnostic accuracy and efficiency in veterinary care.

The platform optimizes workflow by providing high-quality slide preparation and enabling real-time remote consultation. This CE Mark certification affirms the system's compliance with EU health, safety, and environmental standards, marking a significant milestone for Zomedica's expansion into the European market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.65%
Tags
none
-
Rhea-AI Summary

Zomedica Corp. (NYSE American:ZOM) announced that its Assisi Loop® product line continues to be designated as a Fear Free Preferred Product. Fear Free, a global initiative focused on reducing fear, anxiety, and stress in pets, has reaffirmed its validation of Assisi's targeted pulsed electromagnetic field (tPEMF) technology. This technology is designed to reduce inflammation and pain, accelerate healing, and alleviate canine separation anxiety.

The Assisi Loop® products, including the Assisi Loop Lounge®, are effective for various inflammatory conditions, such as post-surgical recovery, osteoarthritis, internal inflammation, wound care, spinal and nerve disorders, and bone, joint, and soft tissue injuries. The Calmer Canine Anxiety Treatment System® specifically targets the amygdala to reduce canine anxiety.

This continued designation aligns with the increasing demand for non-invasive veterinary care and supports Zomedica's mission to improve the overall quality of life for pets and their owners.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
Rhea-AI Summary

Zomedica Corp. (NYSE American:ZOM) has introduced advanced audio capabilities for its VETGuardian Zero-touch remote vital signs monitoring system. The new features include real-time audio streaming, recorded playback functionality, and customizable alerts. These enhancements aim to revolutionize remote patient monitoring in veterinary medicine by providing veterinarians with more comprehensive insights into animal health.

The VETGuardian system is now the only product on the market offering contactless vital sign monitoring combined with live video and audio feed. This unique combination allows for detailed remote assessments of animals, enabling early detection of distress signs, evaluation of treatment responses, and more precise care delivery. The audio recording feature also supports improved documentation and medical record-keeping, facilitating better-informed decision-making in veterinary care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
none

FAQ

What is the current stock price of Zomedica (ZOM)?

The current stock price of Zomedica (ZOM) is $0.0973 as of March 5, 2025.

What is the market cap of Zomedica (ZOM)?

The market cap of Zomedica (ZOM) is approximately 95.3M.

What is the core business of Zomedica Corp?

Zomedica Corp focuses on providing innovative diagnostic and therapeutic solutions for veterinary applications, enhancing care for companion and equine animals.

Which markets does Zomedica serve?

The company serves the veterinary healthcare market with products used in both companion animal and equine practices across domestic and international regions.

What type of products does Zomedica offer?

Zomedica offers a range of point-of-care diagnostic platforms, imaging systems, and therapeutic devices designed to streamline practice workflows and improve patient outcomes.

How does Zomedica differentiate itself in the veterinary industry?

By integrating advanced technology with clinically-driven insights, Zomedica delivers precise, rapid diagnostic results and innovative therapeutic solutions that address critical unmet needs in veterinary practices.

What role does the TRUFORMA diagnostic platform play in their offerings?

The TRUFORMA platform provides automated, high-precision diagnostic capabilities at the point of care, reducing turnaround times and enhancing the accuracy of veterinary diagnostics.

How does Zomedica improve operational efficiencies for veterinary clinics?

Their innovative products automate complex diagnostic processes and streamline clinical workflows, leading to faster decision-making, lower costs, and improved patient care.

Why is Zomedica considered an expert in veterinary healthcare?

The company’s commitment to R&D, its science-backed product innovations, and strategic partnerships with veterinary professionals collectively reinforce its reputation for expertise and trustworthiness in the industry.
Zomedica Corp

NYSE:ZOM

ZOM Rankings

ZOM Stock Data

95.35M
961.51M
1.87%
9.37%
4.63%
Medical Devices
Pharmaceutical Preparations
Link
United States
ANN ARBOR